Capro (006380) Stock Outlook 2026: Korea's Only Caprolactam Maker Against Chinese Oversupply

With Capro, you are buying a spread, not a growth story

Owning Capro is not a bet on a company that compounds. It is a bet that the gap between the price of benzene going in and the price of caprolactam coming out will widen. Until an investor internalizes that, Capro looks like a puzzle that never resolves.

My view up front: Capro sits between a flattering label and a hard reality. The label is “Korea’s only caprolactam producer.” The reality is a single-product commodity cyclical crushed by Chinese oversupply. It looks like a monopoly yet has no pricing power. It sits on substantial assets, yet those assets fail to earn money for years at a stretch. Only an investor who holds both faces at once can handle the stock sensibly.

Plenty of retail buyers are drawn in by the phrase “the only domestic maker” and treat Capro as a defensive blue chip. The share price behaves like the opposite. It rallies hard when the chemical cycle turns up and sinks below book value when a supply shock arrives from China. Misclassify the temperament and you end up holding through a loss phase with no thesis, then capitulating at the bottom.

So the first move in analyzing Capro is a mental reclassification: this is a commodity company, full stop. It has nothing in common with a materials name growing through technology penetration. A battery-materials maker adding capacity to win share is playing a different game than a producer riding a mature commodity’s spread cycle, and that distinction shapes everything below.

---

What is caprolactam, and why is Capro the “only” one?

Caprolactam is the monomer for nylon 6. The chain starts at benzene, moves through cyclohexane and cyclohexanone to caprolactam, and polymerizes into nylon 6 resin and fiber. The stockings, the outdoor-jacket fabric, the tire cord reinforcing your tires, fishing nets, and engineering plastics in car parts all trace back to nylon 6.

Capro is the only company producing that caprolactam inside Korea. Its integrated plant in the Onsan complex near Ulsan feeds on benzene and yields caprolactam plus ammonium sulfate. Korean nylon makers such as Hyosung TNC, Kolon, and Taekwang Industrial are its natural customers.

Here is the misunderstanding to clear away: “only domestic maker” does not mean monopoly pricing. Caprolactam trades internationally, so if Capro’s price drifts above the global level, its customers simply import Chinese or Southeast Asian caprolactam instead. The international price effectively caps what Capro can charge. Sole-supplier status brings logistics and supply-security benefits, not the power to demand a premium.

This gap between the comfort of the word “monopoly” and the coldness of a real commodity market is the most frequently underestimated part of the Capro thesis.

---

The whole income statement reduces to the spread

Compress Capro’s income statement to one line and you get: caprolactam price minus benzene cost equals spread. Volume and utilization matter, but direction always comes from that margin.

The reason the spread swings so violently explains the earnings amplitude.

Phase	Caprolactam price	Benzene cost	Spread	Capro earnings
Strong nylon demand, stable benzene	Firm	Stable	Widens	Profit, improving
Chinese export volume floods in	Weak	Normal	Narrows	Loss pressure
Oil and benzene spike	Lagged pass-through	Surges	Narrows	Margin damage
Demand and cost both weak	Soft	Soft	Mixed	Direction unclear

Benzene rides the crude-to-naphtha chain and moves with oil, while caprolactam price answers to nylon end-demand and Chinese supply. The two inputs move independently, so the spread resists forecasting and Capro’s quarterly results heave up and down.

The pass-through lag is the specific trap. When benzene rises but the product price cannot follow immediately, the spread compresses and margin erodes. When benzene falls and the product price drops slowly, the spread can briefly widen and produce an “optical profit.” That is why you read Capro’s quarter by the direction and durability of the spread, not the absolute profit figure.

In temperament Capro closely resembles a pure aluminum cyclical. The way LME aluminum prices dictate results at Alcoa (Alcoa) stock outlook is the same mechanism that ties Capro’s profit and loss to the caprolactam spread. In both cases an international commodity price the company cannot control decides the year.

---

How structural is the Chinese oversupply?

The root of Capro’s long slump compresses to one cause: China’s caprolactam self-sufficiency drive.

China once imported large volumes of caprolactam, and in that era Korean, Taiwanese, and Japanese producers profited from exporting there. Then China built out its own caprolactam capacity aggressively. As Sinopec-affiliated plants and domestic majors like Highsun and Luxi kept adding lines, China moved past self-sufficiency into net export.

The effect on Capro comes in two layers. First, an export market vanished. Volumes that used to flow into China stopped, forcing regional producers to fight over the demand that remained. Second, China’s surplus flowed back out, dragging down Asian caprolactam prices outright. When supply chronically exceeds demand, the spread rarely normalizes.

Whether this glut is cyclical or structural is the fork in the road for the Capro thesis. A cyclical glut clears when demand recovers. A structural one eases only when high-cost, aging plants actually close through run-cuts and restructuring. Given the scale of Chinese additions, I read this as largely structural. Expecting a mere demand rebound to restore spreads to their old level is naive. The real turn signal shows up in falling global caprolactam utilization and news of marginal producers cutting output. This same pattern of Chinese capacity dictating price and margin repeats across Korean materials industries, from batteries to display chemicals.

That dynamic is exactly what pressures Korean battery-materials names too. The Chinese capacity overhang running through the cell and cathode chain, discussed in the Samsung SDI (006400) stock outlook, is the same force operating one commodity over: supply growth, not demand, sets the ceiling on margin.

---

Ammonium sulfate: the hidden second P&L

The piece most often dropped from the Capro story is ammonium sulfate fertilizer. The caprolactam process unavoidably generates large volumes of it, and Capro ranks among the sizable ammonium sulfate producers globally.

The appeal is that this is a byproduct made without buying extra feedstock. Whether or not caprolactam sells well, running the process yields ammonium sulfate, and the revenue from selling it effectively defends margin. When the caprolactam spread is at its worst, ammonium sulfate can cushion the size of the loss.

But fertilizer is a commodity too. Strong global grain prices lift farmer fertilizer demand and ammonium sulfate prices, while falling grain prices or a flood of Chinese and Russian nitrogen supply push them back down. Ammonium sulfate is a shock absorber, not a full offset to a caprolactam downturn.

A useful mental model is to see Capro as the sum of a caprolactam spread and an ammonium sulfate spread. Peak earnings come when both are good at once, trough earnings when both are bad. When the two cycles diverge, they partly cancel and results land in an awkward middle.

---

Does the low-PBR asset-value angle hold up?

The other pillar of the bull case is asset value. Long stretches of weak earnings have repeatedly left the share price well below net asset value, which produces the “cheaper than book” argument. The Onsan land and large integrated plant back it.

Taking the low-PBR case seriously requires two distinctions.

First, liquidation value and going-concern value differ. The industrial land Capro holds may be worth a great deal, but as long as the company keeps producing caprolactam, that land is a plant site, not a saleable asset. For asset value to show up in the share price, a catalyst is needed: a return to profit, a business restructuring, or a governance change.

Second, sustained losses erode the asset value itself. Every year of loss shrinks net assets and eats the denominator of the PBR. Buying only because something is “cheap” can mean waiting a very long time. On that axis Capro belongs alongside domestic asset-value cyclicals like Daechang Forging (015230) stock outlook, a name whose earnings swing with the construction-equipment cycle yet also carries a below-asset-value argument. Both share the same problem: the assets exist, but the cycle blocks their realization.

Contrast that with a genuinely low-valuation holding structure backed by operating income. A diversified holding company can trade cheaply while its stakes still generate cash, as with Hanmi Science (008930) stock outlook. Capro’s problem is that in a loss phase the asset base cuts itself down, so the same “cheap” label carries a very different quality of safety.

---

Where should Capro sit in a portfolio?

Placing Capro next to comparable names sharpens the picture.

Stock	Business	Earnings driver	Cycle sensitivity	Defensiveness
Capro (006380)	Single-product chemical	Caprolactam spread, ammonium sulfate	Very high	Low (recurring losses)
Daechang Forging (015230)	Construction-equipment forging	Global equipment cycle	High	Asset value
Alcoa (AA)	Aluminum commodity	LME price, power cost	Very high	Low
SK Telecom (017670)	Telecom services	Tariffs, subscribers	Low	High (dividend)

The table settles Capro’s identity. It is not a defensive stock. It is a textbook commodity cyclical. An investor who wants steady cash flow belongs in a tariff-based defensive like a telecom, and Capro goes in the opposite drawer. Why regulated, subscription-style revenue behaves defensively is clear in the SK Telecom (017670) stock outlook, whose dividend and cash-flow structure stand in sharp relief against Capro’s unhedged commodity exposure.

Capro’s sole-producer status does grant a scarcity premium of sorts. Being the only domestic maker can draw policy attention around nylon supply-chain security and can earn a re-rating as irreplaceable domestic volume when the cycle turns. But that scarcity is limited in front of the cold arithmetic of a commodity spread.

For a globally accessible pure-play comparison, US-listed AdvanSix (ASIX) is the closest analog. Spun off from Honeywell, it is an integrated caprolactam, nylon 6, and ammonium sulfate producer whose structure nearly mirrors Capro’s. A US or Latin American investor can track Capro and AdvanSix side by side through the same spread lens.

---

The angle for US and Latin American investors

Two practical points matter for anyone outside Korea.

First, access. Capro is a KOSPI-listed small cap with no ADR, so you cannot buy it through most US or LatAm brokers the way you would a large-cap Korean ADR. You need a brokerage that offers direct Korea-market access, and even then a thinly traded small cap can be hard to size. If direct access is a barrier, AdvanSix (ASIX) offers a listed, liquid proxy for the same caprolactam-spread trade.

Second, currency. All Capro exposure carries KRW/USD risk stacked on top of the commodity risk. A strong dollar shrinks a US investor’s gains when converting back, while a weak dollar amplifies them. For a Latin American investor the local-currency-to-KRW path adds a further layer. You are taking a cyclical chemical bet and a Korean won bet at the same time, and both should be sized deliberately. The broader logic of sizing volatile sector bets within a diversified book is covered in the AI stock investing guide 2026, and the cross-border tax mechanics that follow from holding foreign equities are laid out in the overseas stock capital gains tax guide.

---

What to watch every quarter

Knowing what to read first at each result keeps you from getting whipsawed by headline revenue.

First: the caprolactam-benzene spread. Direction and width beat absolute profit. An improving spread keeps a turnaround thesis alive; a narrowing one means you should doubt the durability of any reported profit.

Second: Chinese caprolactam utilization and export volume. Falling Chinese utilization and shrinking exports signal easing Asian supply pressure. Fresh Chinese line startups mean any spread recovery gets delayed.

Third: nylon 6 end-demand. Watch whether apparel fiber, tire cord, and engineering plastics demand is reviving. Weak downstream leaves nothing to push caprolactam prices up.

Fourth: ammonium sulfate price and grain prices. How much the fertilizer spread defends against a caprolactam slump determines the size of the loss. Firm grain prices favor ammonium sulfate.

Fifth: the swing back to operating profit. The market ultimately re-rates on “has it stopped losing money.” Share prices tend to react sharply in the first quarter of a return to profit.

Read those five together and you can judge Capro’s position in the cycle yourself, without being led around by a headline sales number.

---

Further reading

• 👉 Alcoa (Alcoa) Stock Outlook 2026: Aluminum Commodity Cycle and High Beta
• 👉 Daechang Forging (015230) Stock Outlook 2026: Construction-Equipment Cycle and Asset Value
• 👉 Samsung SDI (006400) Stock Outlook 2026: Battery Materials and Chinese Capacity
• 👉 SK Telecom (017670) Stock Outlook 2026: Defensive Cash Flow and Dividend
• 👉 AI Stock Investing Guide 2026: Core Names and ETF Selection

---

This article is an investment opinion written for informational purposes and does not recommend buying or selling any specific security. Stock investing carries the risk of principal loss, and every investment decision should be made on your own judgment after considering your financial situation and risk tolerance. Any business status or outlook mentioned here reflects the time of writing; always verify the latest disclosures and professional advice before investing.